

1 **Evolutionary history of Calcium-sensing receptors sheds light into hyper/hypocalcemia-  
2 causing mutations**

3 Aylin Bircan<sup>1</sup>, Nurdan Kuru<sup>1</sup>, Onur Dereli<sup>1</sup>, Oğün Adebali<sup>1,2\*</sup>,

4

5 **1** Faculty of Engineering and Natural Sciences, Sabancı University, İstanbul, Türkiye

6 **2** TÜBİTAK Research Institute for Fundamental Sciences, Gebze, Türkiye

7

8 \* [oadebali@sabanciuniv.edu](mailto:oadebali@sabanciuniv.edu)

9 **Abstract**

10 The Calcium Sensing Receptor (CaSR) is very important in controlling the levels of calcium in  
11 the body by interacting with different types of G-protein. This receptor is highly conserved  
12 among other G-protein coupled receptors (GPCRs) and has been linked to disorders affecting  
13 the balance of calcium in the body, such as hypercalcemia and hypocalcemia. Although there  
14 has been progress in understanding the structure and function of CaSR, there is still a lack of  
15 knowledge about which specific residues are important for their function and how it differs from  
16 other receptors in the same class. In this study, we used phylogeny-based methods to identify  
17 functionally-equivalent orthologs of CaSR, predict the importance of each residue, and calculate  
18 specificity-determining position (SDP) scores to uncover the evolutionary basis of its function.  
19 Our results showed that the CaSR subfamily is highly conserved, with higher SDP scores than  
20 its closest receptor subfamilies. Residues with high SDP scores are likely to be critical in  
21 receptor activation and pathogenicity. We applied gradient-boosting trees with evolutionary  
22 metrics as inputs to predict the functional consequences of each substitution, and discriminate  
23 between gain and loss-of-function mutations those causing hypo- and hypercalcemia,  
24 respectively. Our study provides insight into the evolutionary fine-tuning of CaSR, which can  
25 help understand its role in calcium balance and related disorders.

26 **Introduction**

27 Calcium sensing receptor (CaSR) is a class C G-protein-coupled receptor (GPCR) that  
28 maintains extracellular Ca<sup>2+</sup> homeostasis by sensing calcium ions in the blood and regulating  
29 parathyroid hormone release and urinary calcium[1, 2]. The CaSR is activated by Ca<sup>2+</sup> and L-  
30 amino acids such as L-Phe and L-Trp as well as polyamines and polypeptides[3-5]. Ligands  
31 bind to the extracellular Venus flytrap (VFT) domain of the receptor-like the other class C  
32 GPCRs such as metabotropic glutamate receptors [6].

33 Class C GPCRs are obligatory dimers, forming either homo or heterodimers [6]. CaSR forms a  
34 homodimer where each subunit is composed of an extracellular domain (ECD), comprising a  
35 bilobed (LB1, LB2) VFT and a cysteine-rich domain (CRD) connected to a heptahelical  
36 transmembrane (7TM) domain[3, 5].  
37 Crystal structures of the ECD [4, 7] and cryo-electron microscopy structures of the full-length  
38 CaSR[3, 5, 8-10] reveal the structural basis for activation mechanisms and ligand binding sites.  
39 L-amino acid binding site at the interdomain cleft of LB1-LB2[3-5, 11-13] and multiple Ca<sup>2+</sup>  
40 amino acid binding sites on the VFT domain are shown in the literature[3-5]. While Ca<sup>2+</sup> is the  
41 composite agonist to the CaSR, L-amino acids promote the receptor activation along with the  
42 Ca<sup>2+</sup>, but they are not able to activate the receptor alone[14]. Even though Ca<sup>2+</sup> alone  
43 activates the receptor in functional assays[14], whether it activates the CaSR in the absence of  
44 L-amino acid is still controversial[3, 5].  
45 Variants in CaSR may cause malfunctions that result in Ca<sup>2+</sup> homeostasis diseases in humans.  
46 More than 400 germline loss/gain-of-function mutations cause hypercalcaemic disorders,  
47 neonatal severe hyperparathyroidism (NSHPT) and the milder familial hypocalciuric  
48 hypercalcemia type-1 (FHH1) and autosomal dominant hypocalcemia type-1 (ADH1)  
49 respectively[2]. Many more CaSR variants are anticipated to be identified as more population-  
50 level genetic data become available[2]. Understanding the role of each residue in receptor  
51 structure and activation mechanisms could provide additional information about the likelihood of  
52 variant pathogenicity and CaSR signaling. The role of each residue in a receptor can be  
53 revealed by comparison of receptors in a family and between different families; however, the  
54 structure and complete activation mechanisms of many families in class C GPCRs are still  
55 unknown, especially G-protein coupled receptor family C group 6 member A (GPRC6A) and  
56 type 1 taste receptors (TAS1Rs; members 1,2 and 3) that are the closest subfamilies to CaSR.  
57 While all subfamily receptors of class C GPCRs share common domains and structural features,  
58 details of responding to different ligands and activating signaling pathways are diverse between  
59 even closely related receptors[6]. Gene duplication is the main mechanism that generates new  
60 protein functions across GPCRs. Protein families are evolved by speciation events following a  
61 gene duplication[15, 16]; thus sequence comparisons of members within a subfamily and  
62 between subfamilies can show the evolutionarily conserved domains as well as diverged protein  
63 sites that distinguish one subfamily from others. One challenge with this analysis is that  
64 excessive gene duplication events complicate the identification of functionally identical orthologs  
65 in a subfamily. Moreover, the conservation patterns in paralogs and distant homologs may help

66 inferring the specific roles of a single residue in protein function. Because the evolutionary  
67 pressure on the paralogs and close orthologues are not the same, allowed substitutions on  
68 paralogs may not be acceptable in close orthologues. Thus, using functionally identical  
69 orthologs in sequence comparisons is crucial to infer the role of each residue in a protein family.  
70 Here, we show the importance of each residue in CaSR by comparing it with the closely related  
71 subfamilies, GPRC6A and TAS1Rs. We identified all orthologues sequences in each subfamily  
72 by phylogenetic tree analysis. To obtain orthologues without requiring computationally  
73 expensive phylogenetic tree step, subfamily-specific profile HMMs are generated from the true  
74 orthologues in subfamilies that we determined by the phylogenetic tree analysis. We calculated  
75 a specificity score for each residue in a subfamily by calculating scores based on a modified  
76 version of PHACT[17] scores which considers independent evolutionary events on the  
77 phylogenetic tree while scoring the acceptability of an amino acid substitution. We predicted the  
78 functional consequence of each substitution in CaSR by using the gradient boosting trees  
79 machine learning approach.

## 80 **Results**


### 81 **Evolutionary History of Class C GPCRs**

82 To reveal the evolutionary constraints on protein families, we developed to develop a strategy to  
83 precisely define a protein subfamily. Precise subfamily definition can be precisely accomplished  
84 by revealing the evolutionary history of the superfamily. Evolutionary history of gene families  
85 can only be established by reconstructing high-quality phylogenetic trees, which can be used to  
86 pinpoint gene duplication events. Discrimination between gene duplication and speciation nodes  
87 enabled us to define of the paralogous and orthologous protein sequences. We further analyzed  
88 the phylogenetic trees to classify the orthologous sequences that are likely equivalent in  
89 function. We used functionally-equivalent orthologs in comparative analyses between  
90 subfamilies, which eventually yielded subfamily-specific signatures that can be used to define  
91 that particular subfamily and its function. Finally, the association between the signature and  
92 function would enable a better understanding of specific molecular mechanisms and the effects  
93 of variants, particularly for the protein subfamily of interest. Here, we aim to reveal the  
94 signatures of the CaSR subfamily, that is implied in the specific function of calcium-sensing and  
95 downstream signaling.

96 We have retrieved the complete proteomes of 478 species from the NCBI database. To identify  
97 proteins that belong to class C GPCR family, we performed searched profile HMM of the seven  
98 transmembrane domain profile (Pfam: 7tm\_3) (Fig 1) against the proteomes. While this search

99 allowed us to retrieve the entire class C GPCRs hitting the hmm profile, it does not yield  
100 subfamily (22 human GPCRs) annotations. We performed scan profile HMM of the PfamA  
101 profile against to Class C GPCR to select canonical isoforms. We used seven-transmembrane  
102 domain only to assign subfamilies and trimmed the N-terminus region of this domain for further  
103 homology steps. To generate a general HMM profile for each subfamily, we first applied a Blast  
104 search using each human class-C as a query. For each subject, we blasted them against the  
105 human proteome. We retrieved the bidirectional best hits (Core subfamily assignment).

106



107

108 **Figure 1: Summary of the Methodological Framework.** 478 complete proteomes were retrieved from NCBI  
109 database. Each sequence was searched by HMMsearch against Pfam 7tm\_3 domain profile to retrieve all class C  
110 GPCRs. Domain architectures of class C GPCRs were determined by HMMscan against PFAM.A profile to identify  
111 canonical isoforms. Species-specific BLAST databases from TM domains of the canonical isoforms were built. Bi-  
112 directional mutual best hits were detected by blasting each canonical sequence against the species databases (Core  
113 subfamily assignment). Core subfamily sequences were aligned and ML trees were built to make subfamily profile  
114 HMMs. By HMMsearch against subfamily profile HMMs other sequences in the subfamilies were found (Subfamily  
115 extension). Sequences in each subfamily were aligned and ML trees were built. Based on the ML trees paralogs were  
116 filtered and functionally identical groups were identified (FIG).

117 For proteins that did not have bidirectional mutual best hits, we assigned them to a subfamily  
118 based on their homology search against the HMM profiles generated in the previous step

119 (Subfamily Extension). We produced maximum likelihood (ML) trees of extended subfamilies  
120 and filtered paralogous sequences to obtain functionally identical groups (FIGs).

121 The CaSR subfamily produced over five thousand hits, which included vomeronasal and  
122 olfactory receptors that have never been shown to sense calcium. Previous research has shown  
123 that CaSR is classified in the pheromone/olfactory cluster of class C GPCRs[18] (18). In species  
124 that had multiple proteins assigned to the CaSR subfamily, we constructed a maximum  
125 likelihood tree using these hits and other human class C GPCR protein sequences. These trees  
126 revealed that a significant number of duplication events occurred in the species after the clade  
127 diverged from CaSR. As a result, we defined this diverged clade as a new subfamily named  
128 CaSR-likes. The sequences in this subfamily is unlikely to maintain calcium homeostasis, and  
129 therefore should not be annotated as calcium-sensing receptors.

130 We selected representative sequences from different species for each subfamily of 22 different  
131 receptor subfamilies and 264 CaSR-like sequences and built a ML tree (Fig 1A). Also, we built  
132 the ML trees of all proteins from CaSR, GPRC6A, taste receptors and merged these trees to the  
133 representative tree of class C GPCRs (Fig 2 A). The resulting phylogeny shows that are five  
134 major clades: CaSR-related, GABA, mGluR, Orphans, and retinoic acid induced (RAIG).  
135 Orphan receptors, GPR158 and GPR179, formed a clade that was diverged from other  
136 receptors consistent with previous trees[19] and with 0.95 transfer bootstrap (TB) value.  $\gamma$ -  
137 aminobutyric acid<sub>B</sub> receptors (GABBR1 and GABBR2) formed another clade diverged from  
138 GPR156 with 0.97 TB.  $\gamma$ -aminobutyric acid<sub>B</sub> receptors evolved earliest that have a common  
139 ancestor with the highest taxonomic rank (33213–Bilateria) compared to other subfamilies.  
140 CaSR group (CaSR, CaSR-likes, GPRC6A and taste receptors) was diverged from  
141 metabotropic glutamate receptors (GRM1-8) and RAIG receptors (GPRC5A, GPRC5B,  
142 GPRC5C, GPRC5D) with 1 and 0.98 TB values respectively. Within the CaSR group clade  
143 CaSRs and CaSR-likes were diverged from GPRC6A and taste receptors with 1 TB. Except  
144 TAS1R1 and TAS1R2, all CaSR group subfamilies have a common ancestor from taxonomy  
145 clade 7776-Gnathostomata. TAS1R1 and TAS1R2 were more specific than other CaSR group  
146 subfamilies that were evolved from 117571-Euteleostomi. Comparison analysis of branch  
147 lengths[20] among common species between CaSR, GPRC6A and taste receptors shows that  
148 CaSR subfamily is significantly more conserved than its closest subfamilies (Fig 2 B)

149 The higher diversity of CaSR-likes relative to CaSRs is reflected in the ML tree (Fig 2A). Branch  
150 lengths of CaSR-likes are longer in contrast to shorter branch lengths in CaSR. Longer branch  
151 lengths show that more variation, and thus divergence occurred in the CaSR-like clade.

152 Moreover, extensive gene duplication events occurred in this clade. For instance, rodents such  
153 as *Dipodomys ordii* (taxid:10020), *Octodon degus*(taxid:10160) and snakes such as  
154 *Notechis scutatus*(taxid: 8663) have more than a hundred receptors that match to CaSR profile.  
155 However, these matches include type 2 vomeronasal receptors (V2R) and type 2 vomeronasal  
156 receptor likes. Among mammals, V2R genes exhibit significant variation. While dogs, cows, and  
157 primates except prosimians do not have functional V2Rs, rodents, reptiles and fish have  
158 multiple intact V2Rs[21].Since these receptors do not have functional orthologs in mammals,  
159 separating them from functionally-equivalent CaSRs is crucial.


160

161

A



B



162


163 **Figure 2: Evolution of Class C GPCRs.** (A) The maximum likelihood phylogenetic tree of Class C GPCRs,  
164 spanning representative species from each subfamily is shown. Subfamilies are represented as circular layers around  
165 the ML tree. All twenty-two Class C GPCR subfamilies are shown in the inner circle. In addition to these subfamilies,  
166 vomeronasal and other orphan receptors are represented as CaSR-like receptors. All proteins in CaSR, GPRC6A  
167 and TAS1Rs are merged to this representative species tree. (B) Branch lengths from leaf to the root of the common  
168 species that exist in all CaSR, GPRC6A and TAS1Rs are taken from the subfamily trees. Welch's t-Test by using  
169 ggstatsplot package results are shown on the graph.

170 ***Subfamily-specific Profile HMMs to Obtain Orthologs***

171 In the class C GPCR family, gene duplication events give rise to new specificity, and each  
172 duplicated gene with a new function is evolved by further speciation events and produce a set of  
173 orthologous sequences[15, 16]. Each subfamily of class C shares relatively conserved  
174 membrane-spanning region as well as a degree of variability underling functional differences. At  
175 the molecular level, residues that are responsible for certain functional characteristics such as  
176 ligand and coupling selectivity are called specificity-determining residues[15]. Conservation  
177 analysis from multiple sequence alignments can be used to find residues that are conserved in  
178 all subfamilies through evolution as well as specificity-determining residues that are only  
179 conserved in a subfamily and differ in other subfamilies. However, the success of this method  
180 depends on the sequences that are used to build alignments. Hence, it is vital to use  
181 functionally identical orthologs in the analysis.

182 The seven-transmembrane domains of class C GPCRs are used to build a class-specific  
183 general profile for this family (Pfam:7tm\_3). However, this domain cannot be used to  
184 differentiate subfamilies further.

185 Moreover, excessive gene duplication events as seen in the CaSR-like clade requires precise  
186 phylogenetic analysis to differentiate CaSR and CaSR-like sequences. Also, subfamily specific  
187 profile HMMs are shown to be promising methods to detect protein sequences belong to a  
188 protein subfamily, as well as separation of homologs and non-homologs [22, 23].Therefore, we  
189 built subfamily-specific profile HMMs that match with all orthologs of a subfamily while excluding  
190 closely related like sequences (Fig 3).



191

192 **Figure 3: Subfamily Specific HMM Models.** Subfamily specific HMM model method. Based on the phylogenetic tree  
 193 the target, the closest and the rest groups are determined. Representative amino acids in each group are selected,  
 194 and their scores are calculated. Weights to scale the emission probability are calculated.

195 We define the target family, its closest family (phylogenetic neighboring clade), and the rest  
 196 based on the phylogenetic tree. We weighted the identity score of each amino acid to calculate  
 197 the emission probabilities. The highest weight is given to the residues which are only conserved  
 198 in the target subfamily; hence they differentiate one subfamily from the others. Minimum weight  
 199 is given to the residues which are conserved both in the target subfamily and its closest clade.  
 200 We tested our subfamily-specific profile HMMs' performance on an independent sequences  
 201 retrieved UNIPROT dataset[24] and not seen during the training process. We assigned  
 202 sequences to their corresponding subfamilies by following the same steps as NCBI dataset[25]  
 203 used to build these models. We selected new taxons that were not in the NBCI dataset as test  
 204 sequences. Our subfamily-specific profile HMMs correctly hit all members of a subfamily while  
 205 they do not hit any protein from another subfamily (Table 1).

206

207 *Table 1: Subfamily Specific Profile HMM's Performance*

Subfamily HMM	Test Cases	Hits	Missed
CaSR	81	81	-
GPRC6A	62	62	-
TAS1R1	75	75	-
TAS1R2	21	21	-
TAS1R3	74	74	-

208 **Specificity Determining Residues**


209 CaSR is distinguished from other subfamilies of class C GPCRs by its oversensitivity to many  
210 substitutions that are caused either gain or loss of function mutations, because it maintains  
211 systemic calcium homeostasis and highly sensitive to a very slight change in extracellular Ca<sup>2+</sup>  
212 concentrations[26]. Since CaSR is the most conserved and ancestral subfamily among the  
213 CaSR-likes, GPRC6A and TAS1Rs, it is reasonable to expect in some positions can be under  
214 the relaxation of existing purifying selection in any CaSR-likes, GPCR6A or TAS1Rs, but not in  
215 CaSR. On the other hand, at some positions the same amino acid remains functionally  
216 important in both subfamilies, and at others a position remains important in each subfamily but a  
217 different amino acid is favored in each duplicate.

218 To identify and order residues that differentiate a subfamily from its closest relatives, we  
219 employed multiple sequence alignment- and phylogenetic tree-based approaches. Specificity-  
220 determining residues that are conserved in a subfamily, but differ from its sister clade can be  
221 predicted by directly comparing ancestral family sequences and calculating their divergence  
222 scores (26). However, using multiple sequence alignments only does not discriminate between  
223 the number of substitution event. For example, a single substitution event in the common  
224 ancestor of bony fish clade of CaSR subfamily can be inherited to multiple descendants'  
225 sequences. Assessing this single event as independent events result in overcounting of these  
226 changes as if they are independent. Hence, the position is considered (i) to tolerate that  
227 particular amino acid and (ii) functionally less important. In contrast, a single evolutionary event  
228 might have been compensated by other substitutions in the same evolutionary node. Such a  
229 substitution might not be tolerated in the other clades of the subfamily.

230 Another consideration to identify and order specificity-determining residues is treating  
231 substitution events on the phylogenetic tree unequally. When an amino acid in CaSR remains  
232 the same but can differ in the nearby subfamily, CaSR-likes, it indicates that the amino acid has  
233 a unique purpose for CaSR. The SDP score of such an amino acid must be high. If an amino  
234 acid is conserved in both CaSR and remote subfamilies like taste receptors but likely to be  
235 substituted in CaSR-likes, it suggests that the amino acid plays a common functional role in  
236 both CaSR and other subfamilies. For such an amino acid, the SDP score must be low, since it  
237 is not a specific position for CaSR.

238 For CaSR group(CaSR, GPRC6A and TAS1Rs), we identified and order residues by specificity  
239 which differentiate a subfamily from others by using an adaption of functionally divergent  
240 residues method[27] along with an adaption of PHACT method[17]. We calculated probability of

241 each amino acid at each node of the CaSR-group phylogenetic tree by ancestral sequence  
242 reconstruction (Fig 4 A). Starting from the root of the tree, we identified each substitution event  
243 and at which subfamily node that event happened. Counting the number of independent  
244 substitution events in a subfamily clade and comparing the probability of the same substitution  
245 in other subfamily clades, we ordered the specificity-determining residues. We assumed that if  
246 an amino acid is allowed to change on sister subfamily nodes and poorly conserved in sister  
247 subfamily nodes while it is highly conserved on the target subfamily node, it is a specific residue  
248 to the target subfamily only. If a substitution event is observed on a clade close to the target  
249 node, we consider that event to increase specificity of a residue because it diverges the target  
250 group from its closest, sister clade. The details and the algorithm are given in materials and  
251 methods (Algorithm 3).



252

253

254 **Figure 4: Specificity Determining Position Scores.** (A) Calculation of SDP scores uses the phylogenetic tree, probability distribution of amino acids at each ancestral node. (B) SDP score distributions of each subfamily are shown. (C) Cryo-EM structure of human CaSR bound with  $\text{Ca}^{2+}$  and L-Trp (PDB:7DTV) and homology models of

257 *GPRC6A, TAS1R1, TAS1R2 and TAS1R3 are colored based on SDP scores. Residues with high SDP score (above*  
258 *5.0) are shown as spheres.*

259 We calculated specificity scores for each CaSR, GPRC6A and TAS1Rs. Specificity score  
260 distributions show that CaSR subfamily have more specific residues compared to other  
261 subfamilies (Fig 4 B). On the VFT domain, specific residues are clustered different regions. We  
262 found a cluster of specific residues on the interdomain cleft between LB1-LB2 that is the L-  
263 amino acid binding site in other class C GPCRs[3]. It suggests that this region is the primary  
264 Ca<sup>2+</sup> binding site in CaSR consistent with[14]. We found two different clusters of specific  
265 residues on the ECD. First cluster was on the LB1 domain and on the LB1-LB1 dimer interface.  
266 LB1 domain plays a role in anchoring ligands and initiating domain twisting by conformational  
267 changes at the interface between LB1 regions[3, 5]. The second cluster was found at the  
268 cytosolic side of the LB2 and at the interface between LB2-CRD where Ca<sup>2+</sup> ions are bind[3-5].  
269 Interaction between LB2 subunits are required for CaSR activation that propagates to large-  
270 scale transitions of the 7TMDs[3, 5]. Specific residues on the LB1 domain, LB1-LB1 dimer  
271 interface and LB2-CRD interface indicate that they provide the structural conformational  
272 changes upon ligand binding to the interdomain cleft. Mutations located on these regions are  
273 associated with loss and gain of function mutations (Fig 6)[2]. Other specific residues are found  
274 on the CR, ECL2 and TM domains. On the ECL2 acidic residues D758 and E759 are specific to  
275 CaSR. The intersubunit electrostatic repulsion between the ECL2 regions could facilitate the  
276 activation of CaSR[3, 5]. In the agonist+PAM bound state the ECL2 is moved by the interaction  
277 among E759, W590, and K601. Deletion of D758 and E759, and single mutations of K601E and  
278 W590E disrupts the CaSR activity, however Δ758–759 mutant was expressed at the cell surface  
279 with the comparable levels to that of WT, while W590E and K601E mutants were expressed on  
280 the cell surface lower than the WT level[3]. We found that residues W590 and K601 are not  
281 specific to CaSR. The TM domains of two protomers of CaSR come into close proximity upon  
282 receptor activation[5].


283 The orientation of the TM5-TM6 dimer in the CaSR distinguishes it from other Class C receptors  
284 such as mGluR and GABA<sub>B</sub> receptors, which results in its inactive conformation[9]. The  
285 interaction between TM4-5 of each subunit in the inactive state is essential[14], while the  
286 interaction between TM6-TM6 is crucial for the active state[3, 8, 14]. The structural findings and  
287 the presence of CaSR specific residues on each TM domain suggest that CaSR is specialized  
288 in both dimerization and ligand binding. Specific residues on TM domain guarantees the correct  
289 orientation for activation upon ligand binding and inactive conformation otherwise. Interactions  
290 between the domains and ligand-receptor are quite sensitive that slight changes cause

291 malfunctions in the receptor. On the other hand, GPRC6A and taste receptors are more prone to  
292 acceptable substitutions and they are not very specialized to respond a single ion. GPRC6A and  
293 taste receptors are activated by a broad spectrum of ligands[28, 29]. Even though the ligand of  
294 GPRC6A is controversial in the literature, multiple ligands such as osteocalcin (Ocn),  
295 testosterone, basic amino acids and cations such as L-Arg, L-Lys, L-Orn, calcium, magnesium,  
296 and zinc are suggested to bind GPRC6A[29]. Taste receptors bind to different ligands including  
297 sugar, L- and D-amino acids, sweet proteins, and artificial sweeteners[30].  
298 On the TM region we also find CaSR specific cholesterol recognition/interaction amino acid  
299 consensus (CRAC) motif (L783,F789,S820) that is defined by the consensus (L/V)X1–5YX1–  
300 5(R/K) and is often present at junctions between membrane- and cytosol-exposed domains and  
301 shown in GRM2 receptor[31]. Phylogenetic analysis shows that TAS1R3 evolved earliest (7776  
302 Gnathostomata) among TAS1Rs, TAS1R1 and TAS1R2 subfamilies have common ancestor  
303 117571 Euteleostomi. TAS1R3 forms heterodimers with TAS1R1 and TAS1R2[28, 30, 32].  
304 Interactions between the cytosolic terminus of the extracellular CRD is needed for T1R3  
305 dimerization. TAS1R1 and TAS1R2 recognize a broad spectrum of L-amino acids that bind to  
306 the intercleft between LB1-LB2 and induce the positional shift of the CRD regions, however  
307 T1R3 loses the corresponding function[32]. Our analysis showed that TAS1R1 have specific  
308 residues on LB1, LB2 and extracellular loop regions. Also, TAS1R2 has specific residues on  
309 LB1,LB2 and CR domains. On the other hand, in TAS1R3, we found specific residues only on  
310 the LB1 and one on the CR domain. Since LB1-LB2 domains create a cavity for ligand binding,  
311 specific residues on LB1-LB2 domains of TAS1R1 and TAS1R2 may contribute to domain  
312 transformation upon ligand binding. However, the number and distribution of specific amino  
313 acids suggest that taste receptors are not under selective pressure as CaSR.


314 **Gradient Boosting Trees Machine Learning Approach to Predict the Mutation Types in**  
315 **CaSR** Because CaSR is a highly conserved subfamily, any substitution on the receptor disrupts  
316 the function of the receptor and causes either gain or loss of function mutations (Fig 3C).  
317 However, predicting the functional consequence of a substitution is challenging. Evolutionary  
318 conservation of a residue among subfamilies might reflect the common structural constraints,  
319 but it does not distinguish between loss and gain of function mutations (i.e., LoF and GoF,  
320 respectively). In addition, at some positions substitution to different amino acids causes either  
321 loss or gain of function mutations[21]. We hypothesized that “activating” mutations are more  
322 likely to be tolerated in the neighboring clades such as GPRC6A and TAS1Rs and not in CaSR  
323 whereas, in general, loss-of-function (inactivating) mutations are not tolerated in the larger clade  
324 of these receptor subfamilies. To test this hypothesis whether we can discriminate between GoF

325 and LoF mutations in CaSR, we applied a tree boosting machine learning algorithm,  
326 XGBoost[33] that linked multiple features such as conservation scores, physico-chemical  
327 properties of amino acids and domain information.  
328 We used sequence-based features, identity scores from multiple sequence alignments, physico-  
329 chemical properties of amino acids, and domain information as input features to train our model  
330 (Fig 5 A). Since we calculated our feature values from the multiple sequence alignments, we  
331 divided our dataset into training, validation and test datasets before we created feature matrices  
332 to prevent information leakage. We performed 50 replications with different random splitting of  
333 datasets to obtain a more robust model performance.

**A**



**B**



334  
335 **Figure 5: Gradient Boosting Trees Machine Learning Approach to Predict the Mutation Types in CaSR.**  
336 **(A)**Model architecture. We used MSA of CaSR,CaSR-likes, GPRC6A and TAS1Rs to generate features as well as  
337 amino acid physico-chemical features and domain information. We performed 50 replications. **(B)** The performance  
338 and feature importance of XGBoost algorithm. AUROC and AUPR values of 50 replications are shown. Average AUC  
339 levels of 50 replications are 0.83 and 0.78 for the train and test respectively. Average AUPR levels of 50 replications  
340 are 0.93 and 0.9 for the train and test respectively. Contributions of Shapley values for type of pathogenicity  
341 classification to the model output for XGBoost. aa0:the amino acid found in the human CaSR,aa1:substituted amino

342 acid, AF: average flexibility, TMT: TM tendency, ZP: Zimmerman polarity, B:BLOSUM62,AWR:atomic weight  
343 ratio, TM:transmembrane domain


344 *Table 2: Model's predictions for the new CASR gain and loss of function mutations from the literature. The correct*  
345 *predictions are indicated by a star symbol (\*) next to them.*

Mutation	Cause	Prediction
p.I857S[34]	hypocalcemia	gain-of-function*
p.Y825F [35]	hypocalcemia	gain-of-function*
p.P393R [36]	hypercalcemia	loss-of-function*
p.C60G[37]	hypercalcemia	loss-of-function*
p.D99N[38]	hypercalcemia	loss-of-function*
p.T186N[39]	hypocalcemia	loss-of-function
p.A840V[24]	hypocalcemia	gain-of-function*
p.S448P[40]	hypercalcemia	loss-of-function*
p.L696V[41]	hypocalcemia	gain-of-function*
p.D433Y[42]	hypercalcemia	loss-of-function*
p.S147L[43]	hypercalcemia	loss-of-function*
p.D398N[44]	hypercalcemia	loss-of-function*
p.K805R[45]	hypercalcemia	gain-of-function
p.C60Y[46]	hypercalcemia	loss-of-function*
p.S820N[47]	hypocalcemia	loss-of-function
p.L606P[48]	hypercalcemia	loss-of-function*
p.H41R[49]	hypercalcemia	gain-of-function
p.A110D[50]	hypercalcemia	gain-of-function
p.I139T[51]	hypocalcemia	gain-of-function*
p.Q164R[52]	hypercalcemia	loss-of-function*
p.T699N[53]	hypercalcemia	gain-of-function
p.R701G[53]	hypercalcemia	loss-of-function*
p.T808P[53]	hypercalcemia	loss-of-function*

346

347 The ROC and PR curves are used to understand the performance of a binary classifier that  
348 assigns each element of data into two groups. ROC curve is a graphical plot that shows the  
349 false positive rate versus the true positive rate for different threshold values between 0.0 and 1.  
350 A PR curve is a plot of the precision and the recall for different threshold values and it is useful  
351 for imbalance datasets. We used the areas under the ROC and PR curves (i.e., AUC and  
352 AUPR, respectively) to compare the performances of the model on the train and test datasets  
353 for 50 replications. Higher AUC and AUPR values are associated with better performance. AUC  
354 and AUPR over all replications were shown in (Fig 5 B). Our average AUC values for training  
355 and test among 50 replications are 0.83 and 0.78 (Fig 5 B). Our average main AUPR values for  
356 training and test among 50 replications are 0.93 and 0.9 respectively (Fig 5 B). After we  
357 reported our algorithm performance, we trained our algorithm with the whole dataset. We tested  
358 our algorithm with new test cases from literature (Table 2). Additionally, we categorized amino  
359 acids that are observed in the CaSR MSA as neutrals. To date, no pathogenic substitution has  
360 been reported in the literature for these amino acids that we identified as neutral. We visualized  
361 all predictions in the form of a heatmap for every other amino acids at each position until the  
362 disordered region (position 892) of the human CaSR (Fig 6 A). We mapped known CaSR loss  
363 and gain of function mutations on the cryo-EM structure of human CaSR bound with  $\text{Ca}^{2+}$  and L-  
364 Trp (PDB:7DTV (3)) (Fig 6 B). There is a tendency that loss-of-function mutations are on the  
365 outer-core regions, while gain-of-function mutations are on the inner-core regions. In the  
366 heatmap we observed a similar prediction pattern that gain-of-function predictions are mostly in  
367 the inner-core regions. SHAP (SHapley Additive exPlanations) values provide a way to decode  
368 the inner workings of a machine learning model like XGBoost. These values calculate the  
369 average contribution of each feature to the overall prediction, taking into account any  
370 interactions between the features. Based on the SHAP values, the conservation scores of  
371 human CaSR amino acids in other subfamilies play a significant role in the model's prediction,  
372 as shown in Figure 5B. If the amino acid is also conserved in GPRC6A and taste receptors (in  
373 fact conservation score in TAS1R3 has the highest contribution), the model predicts a  
374 substitution of that amino acid as loss-of-function. Another important feature is the domain of the  
375 amino acid. Our findings indicate that if the amino acid is located in the TM domain, a  
376 substitution would result in a gain-of-function mutation. It is known that the majority of gain of  
377 function mutations are located in the TM domain, as shown in Figure 6B. The presence of  
378 certain amino acids on the TM domain of CaSR suggests that they play a crucial role in its  
379 activation mechanism. Even though substituting those amino acids might be acceptable in

380 GPRC6A and taste receptors, they might lead to the loss of TM domains and result in the  
381 overactivation of CaSR.



382  
383 *Figure 6: All Possible Amino Acid Substitution Predictions. (A) Visualizing the precision of our XGBoost model.*  
384 *The heatmap displays the XGBoost model's predictions for each of the 20 amino acids at every position except*  
385 *disordered regions (892-1078) within the human CaSR. (B) Mutations on human CaSR structure. Loss and gain of*  
386 *function associates mutations are shown on the cryo-EM structure of human CaSR bound with Ca<sup>2+</sup> and L-Trp*  
387 *(PDB:7DTV) as blue and red spheres respectively.*

## 388 Discussion

389 In this study, we showed the evolution of CaSR by developing a methodology in precisely  
390 defining functionally equivalent orthologous sequences across species and therefore  
391 subfamilies. We built a high-quality phylogenetic tree of CaSR with its closest subfamilies,  
392 GPRC6A and TAS1Rs. Statistical analysis of branch length distances from this phylogenetic  
393 tree showed that CaSR is evolutionarily more conserved compared to GPRC6A and TAS1Rs.  
394 While GPRC6A and taste receptors can bind to a diverse range of ligands and able to tolerate  
395 substitutions at most of the positions, CaSR requires a delicate balance for proper functioning.  
396 High evolutionarily conservation and specificity of CaSR in contrast to closest subfamilies are  
397 reflected in specificity determining position (SDP) score analysis. CaSR has specific residues  
398 clustered on different regions of the receptor. They are located on Ca<sup>2+</sup> and L-Trp binding sites

399 on the VFT, as well as on the dimerization sites between two sub-units of the homodimer.  
400 Specific residues on the dimer interfaces indicate that dimerization maintained by interactions  
401 between different subunits is required for ligand binding and correct activation of the CaSR.  
402 Ca<sup>2+</sup> ions binding and interactions between LB2-CR domains and conformational changes in  
403 LB1 domain were suggested that they are required to activate CaSR[3-5]. Mutational analysis at  
404 some positions on LB1 domain have been shown to reduce the effect of Ca<sup>2+</sup>-stimulated  
405 intracellular Ca<sup>2+</sup> mobilization in cells[3, 5]. In contrast, substitutions caused negative charge  
406 neutralization on the ECL2 result in prompting the activation of CaSR[5]. Our results suggest  
407 that residues with low SDP scores on any domain are required for common activation  
408 mechanism since they are conserved across functionally different receptor subfamilies.  
409 However, residues with high SDP scores cause malfunctions in the CaSR. Any substitution in a  
410 residue with high SDP score might either cause over or less activation. Deep mutational  
411 scanning approaches or new methods that simultaneously profile variant libraries[54] are  
412 needed to provide further evidence to functionally assay all possible missense mutants.  
413 To predict the functional consequence of a mutation in human CaSR, we used Extreme  
414 Gradient Boosting (XGBoost) method. XGBoost is able to perform well on small datasets by  
415 incorporating variety of regularization methods to control the model complexity, which helps to  
416 prevent overfitting. We have a small and unbalanced dataset in that the number of gain-of-  
417 function mutations was very low, therefore it is prone to overfit. To prevent overfitting while  
418 achieving high predictive performance, we used a simple method along with regularization  
419 parameters. Moreover, we tried to keep the ratio between the number of loss-of-function and the  
420 number of gain-of-function mutations for training and test sets as close as possible. To get a  
421 robust performance, we repeated the train-validation-test splitting procedure fifty times. To  
422 increase the predictive performance, we could use a more complex methods such as deep  
423 learning, however they require larger datasets. Studies that used deep learning or ensemble  
424 methods for similar assessment are different in terms of prediction in which they predict the type  
425 of a mutation as only pathogenic or neutral [55-58]. Even though there are number of mutations  
426 of human CaSR in the Clinvar, the functional consequences of most of them are not known.  
427 Given the constraints of the small dataset and limited additional data, we carefully selected and  
428 processed the features for our model's training. Features that are used to train a machine  
429 learning model heavily determine the performance of the model. The more features we use, the  
430 more information the model has to learn from, which can lead to improved predictive  
431 performance. However, having too many features can also lead to overfitting. Moreover, the  
432 quality of the features is more important than the quantity. One important evolutionary process

433 that can affect the functional consequence of a substitution is co-evolution. From the multiple  
434 sequence alignment of CaSR proteins, we manually selected six  
435 positions, p.180, p.212, p.228, p.241, p.557 and p.883, that are in our dataset and co-evolved. We  
436 masked the co-evolved amino acids from the MSA and performed train-validation-test splitting  
437 procedure fifty times again. Our average AUC values for training and test among 50 replications  
438 were 0.83 and 0.77 respectively, and average AUPR values were 0.93 and 0.89. Despite not  
439 experiencing an improvement in performance, we found that the amino acid changes p.I212T,  
440 p.F180C, and p.I212S were now predicted to cause loss of function, contrary to their previous  
441 prediction of causing gain of function. We cannot accurately assess the impact of co-evolution  
442 on performance because there is a lack of effective tools for identifying co-evolved positions and  
443 our dataset contains only a limited number of co-evolved positions, but we anticipate that it is an  
444 important feature to differentiate gain and loss of function.

445 We built subfamily-specific profile HMMs to get all functionally-equivalent orthologs while  
446 excluding other proteins. To generate these HMM models, we manually decided target, closest  
447 and rest groups based on the phylogenetic tree of CaSR group. Based on the nature of a  
448 phylogenetic tree, selection of these groups is changed, so that this process can be further  
449 automated. We did not anticipate our specific models to match any receptor from other classes  
450 of GPCRs, since they are evolutionarily more distant to CaSR group. We expect that our  
451 subfamily specific profile HMMs can be used to obtain orthologs in different protein families for  
452 the upcoming genomes. They can be particularly useful for studying protein families with many  
453 duplications and orphan protein families, where it can be difficult to identify true members.  
454 These models are particularly important to avoid computationally expensive and expertise-  
455 required phylogenetic tree reconstruction and analysis.

#### 456 **Materials and methods**

##### 457 **Class C Proteins and Their Domain Architectures**

458 478 complete eukaryotic proteomes were downloaded from NCBI genomes website([https://ftp.ncbi.nlm.nih.gov/genomes/archive/old ref seq/](https://ftp.ncbi.nlm.nih.gov/genomes/archive/old_ref_seq/)) in 2018. hmmsearch of HMMER  
459 software[59](<http://hmmer.org/>) was run for each proteome against Pfam 7TM3 profile[60].  
460 Sequences with significant 7TM3 hit based on hmmsearch results (above the default threshold)  
461 were compiled from proteomes. hmmscan of HMMER software[59] (<http://hmmer.org/>) was run  
462 for these sequences against Pfam-A 32.0 database[60]. Based on the results of hmmscan, the  
463 longest isoform was taken and saved in a separate file named by taxonomic id, however  
464 canonical sequences were obtained for human (based on given canonical proteins in UniProt

466 website[61]). Because plants do not have GPCRs, plants were eliminated from the analysis. For  
467 single isoform sequences of each proteome a BLAST database was built[62].

#### 468 **Subfamily Definition and Subfamily Specific Models**

469 Each protein sequence of each taxon was queried through BLASTP against each prepared  
470 BLAST database[62]. reciprocal mutual best hits of each human class C GPCR were collected  
471 in a file named gene id. reciprocal mutual best hits of each class C GPCR and remaining human  
472 class C GPCRs were collected and 7TM domains of these sequences were taken based on  
473 hmmscan results (Longest sequence which hit the 7TM3). Sequences were aligned using  
474 MAFFT v7.221 E-INS-I algorithm with default parameters[63]. Maximum likelihood based  
475 phylogenetic tree (ML tree) of each subfamily of class C GPCR was built using RAxML version  
476 8.2.12 with automatic protein substitution model selection (PROTGAMMAAUTO) and 100 rapid  
477 bootstrapping parameters[64]. Most common lowest taxonomic level was added to the  
478 phylogenetic tree with ETE toolkit[65]. Based on the phylogenetic tree, sequences belong to the  
479 corresponding subfamily were taken and an profile HMM was built. Subfamily Assignment The  
480 process begins by scanning each sequence with a 7TM3 domain against profile Hidden Markov  
481 Models (profile HMMs). After the sequence is scanned, the subfamily is determined based on  
482 three conditions: (1)The maximum score value of the hmmscan must belong to the given  
483 subfamily. (2) E-value is a measure of the significance of a match in a database search and the  
484 lower the E-value, the more significant the match is. The E-value of the sequence must be the  
485 lowest. (3)The sequence must belong to the most common highest taxonomic level of the given  
486 subfamily. Taxonomic level refers to the classification of an organism within a biological  
487 classification system. If a sequence meets these three conditions, it is assigned to the  
488 corresponding subfamily. After this, the full length sequences of each subfamily were then  
489 aligned using the MAFFT v7.221 algorithm[63] and trimmed using the gappy-out method of the  
490 trimAI tool[66].

#### 491 **Paralog Filter**

492 There were a number of duplications in CaSR subfamily. For example, Dipodomys ordii has 116  
493 CaSR sequences. To reduce the number of seqeunces,human CaSR and other human class C  
494 GPCR proteins sequences compiled with CaSR seqeunces of each taxon, and and aligned with  
495 MAFFT v7.221 auto algortihm[63], and the gappy-out method of the trimAI tool was used to trim  
496 the multiple sequence alignments (MSA)[66]. ML tree was built using RAxML-NG v0.9.0 with ML  
497 tree search and bootstrapping (Felsenstein Bootstrap and Transfer Bootstrap) parameters[67].  
498 Based on the ML tree, proteins that were diverged from the common ancestor of the human

499 CaSR clade were classified as CaSR-likes. Proteins that were clustered with the human CaSR  
500 were accepted as CaSRs. After we assigned all proteins to their subfamilies, we built final ML  
501 trees for CaSR, GPRC6A, and TAS1Rs. We added human CaSR sequence was added to  
502 GPRC6A and TAS1Rs subfamilies, and human GPRC6A sequence was added to CaSR  
503 subfamily as an outgroup. We aligned each subfamily sequences with MAFFT v7.221 einsi  
504 algortihm[63] and built the ML trees by using RAxML-NG v0.9.0 with FTT model parameter[67].  
505 We labeled the duplications at each node on the ML trees. Based on the duplications, we  
506 manually checked the trees and removed a clade that was a subset of its sister clade by using  
507 ETE toolkit[65]. We took each branch and node length from leaf to root of the tree by using  
508 common species in all CaSR, GPRC6A and taste receptor trees to calculate subfamily  
509 conservation by using Welch's t-Test by using ggstatsplot package[20].

510 **Subfamily Specific Profile HMMs**

511 [63]. After we took all receptors from CaSR, CaSR-like, GPRC6A, and taste receptors, we  
512 aligned them by using MAFFT v7.221 auto algortihm[63]. For each subfamily we removed the  
513 positions from the multiple sequence alignment (MSA) that correspond to a gap in the human  
514 receptor. Then, we divided the MSA into subfamily alignments. We generated a HMM from the  
515 gap removed alignment of each subfamily, and we added weight to the emission probabilities of  
516 the HMMs. To calculate emission probability weights, based on the maximum likelihood  
517 phylogenetic tree (ML tree) we defined the target, the closest and the rest groups. We took the  
518 closest node as the closest group and other nodes as the rest. According to that we have five  
519 different scenarios:

- 520
  - 521 • CaSR is the target group, CaSR-likes are the closest group, and GPRC6A and taste  
receptors, (TAS1Rs) are the rest.
  - 522 • GPRC6A is the target group, TAS1Rs are the closest group, CaSR and CaSR-likes are  
the rest.
  - 523 • TAS1R1 is the target group, TAS1R2 is the closest group and TAS1R3 is the rest.
  - 524 • TAS1R2 is the target group, TAS1R1 is the closest group and TAS1R3 is the rest.
  - 525 • TAS1R3 is the target group, TAS1R1 and TAS1R2 are the closest group and GPRC6A  
is the rest.

---

**ALGORITHM 1: REPRESENTATIVE AMINO ACID AND INITIAL SCORE FOR POSITION “K”**

---

***Input:*** Representative amino acid of target subfamily,  $R_T$ ; the frequency of  $R_T$  in the  
target,  $S_T$ ; the most frequent amino acid of subfamily  $i$ , ( $i=1, \dots, N$ ) and its frequency,  $a_i$ ,

---

$F_i$ , respectively; the number of subfamilies in close and rest groups,  $n_c$  and  $n_r$ , respectively; conservation threshold for target and close/rest groups,  $thr_1$  and  $thr_2$ ; the threshold for Blosum scores,  $thr_{blos}$ .

**STEP 1:** Choose representative amino acid and related frequency for each group

```
1  for  $j \in \{c, r\}$ 
2    if  $n_j = 1$ 
3       $R_j = a_k$  where  $k$  is the subfamily in group  $j$ 
4       $S_j = F_k$ 
5    else
6      if  $R_T \in \{a_j, j = 1, \dots, n_j\}$ 
7         $R_j = R_T$ 
8         $S_j = F_k$  where  $k$  is the subfamily with the most frequent amino acid is  $R_T$ 
9    else
10       $R_j = a_k$  where  $k$  is group with highest frequency
11       $S_j = \frac{\sum_{s=1}^{n_j} F_s}{n_j}$ 
```

**STEP 2:** Assign position type and initial score to position “ $k$ ”

**Category 1**

```
12  if  $R_c = R_r$  and they are gap
13    if  $R_T$  is gap
14       $type_k = II$ 
15       $score_k = \frac{1}{\sum_{i \in \{T, c, r\}} S_i}$ 
16    else
17       $type_k = I$ 
18       $score_k = \sum_{i \in \{T, c, r\}} S_i$ 
```

**Category 2**

```
19  else if  $R_T$  is gap
```

20      *if  $R_c$  is gap or  $R_r$  is gap*

21       $type_k = II$

22       $score_k = \frac{1}{\sum_{i \in \{T,c,r\}} S_i}$

23      *else*

24       $type_k = I$

25       $score_k = \sum_{i \in \{T,c,r\}} S_i$

### Category 3

26      *else if  $R_T \neq R_c \neq R_r$*

27      *if  $R_T, R_r$  and  $R_c$  are not gaps*

28      *if  $S_T \geq thr_1$  and  $S_c, S_r \geq thr_2$*

29       $type_k = I$

30       $score_k = \sum_{i \in \{T,c,r\}} S_i$

31      *else if  $Blosum(R_T, R_c) \leq thr_{bls}$  and  $Blosum(R_T, R_r) \leq thr_{bls}$*

32       $type_k = I$

33       $score_k = \sum_{i \in \{T,c,r\}} S_i$

34      *else*

35       $type_k = IV$

36       $score_k = \sum_{i \in \{T,c,r\}} S_i$

37      *else if  $R_c$  is gap*

38      *if  $S_T \geq thr_1$  and  $S_r \geq thr_2$*

39       $type_k = I$

40       $score_k = \sum_{i \in \{T,c,r\}} S_i$

41      *else if  $Blosum(R_T, R_r) \leq thr_{bls}$*

42       $type_k = I$

43       $score_k = \sum_{i \in \{T,c,r\}} S_i$

44      *else*

45       $type_k = IV$

```

46       $score_k = \sum_{i \in \{T, c, r\}} S_i$ 
47      else if  $R_r$  is gap
48      if  $S_T \geq thr_1$  and  $S_c \geq thr_2$ 
49       $type_k = I$ 
50       $score_k = \sum_{i \in \{T, c, r\}} S_i$ 
51      else if  $Blosum(R_T, R_c) \leq thr_{bls}$ 
52       $type_k = I$ 
53       $score_k = \sum_{i \in \{T, c, r\}} S_i$ 
54      else
55       $type_k = IV$ 
56       $score_k = \sum_{i \in \{T, c, r\}} S_i$ 

```

#### Category 4

```

57      else if  $R_T = R_c$ 
58       $type_k = II$ 
59       $score_k = \frac{1}{\sum_{i \in \{T, c, r\}} S_i}$ 

```

#### Category 5

```

60      else if  $R_T \neq R_c$  and  $R_T = R_r$ 
61      if  $R_c$  is gap
62       $type_k = III$ 
63       $score_k = \sum_{i \in \{T, c, r\}} S_i$ 
64      else
65      if  $Blosum(R_T, R_c) \leq thr_{bls}$  and  $S_c \geq thr_2$ 
66       $type_k = III$ 
67       $score_k = \sum_{i \in \{T, c, r\}} S_i$ 
68      else
69       $type_k = II$ 

```

70  $score_k = \frac{1}{\sum_{i \in \{T,c,r\}} S_i}$

**Category 6**

71 *else if*  $R_T \neq R_c$  *and*  $R_c = R_r$   
 72     *if*  $S_T \geq thr_1$  *and*  $S_c, S_r \geq thr_2$   
 73          $type_k = I$   
 74          $score_k = \sum_{i \in \{T,c,r\}} S_i$   
 75     *else if*  $Blosum(R_T, R_c) \leq thr_{b1s}$   
 76          $type_k = I$   
 77          $score_k = \sum_{i \in \{T,c,r\}} S_i$   
 78     *else*  
 79          $type_k = II$   
 80          $score_k = \frac{1}{\sum_{i \in \{T,c,r\}} S_i}$

---

**ALGORITHM 2: COMPUTE WEIGHT FOR ALL POSITIONS**

*Input:* Types for each position  $k$  ( $k=1, \dots, K$ ),  $type_k$ ; initial score for each position  $k$  of type  $t$ ,  $score_k^t$ ; number of type  $i$  positions,  $n_i$  where  $n_1 + n_2 + n_3 + n_4 = K$ ; a predefined constant value as max weight of Type II positions,  $c_2$ .

**Weight of Type I positions**

1 *for*  $p_1 = 1: n_1$   
 2      $weight_{p_1} = \frac{score_{p_1}^1}{\min_{l=1, \dots, n_1} (score_l^1)}$

**Weight of Type IV positions**

3 *for*  $p_2 = 1: n_2$   
 4      $weight_{p_2} = \frac{score_{p_2}^2}{\max_{l=1, \dots, n_2} (score_l^2)} \text{mean} (weight_{p_1})_{p_1 \in \{1, \dots, n_1\}}$

**Weight of Type III positions**

5 *for*  $p_3 = 1: n_3$   
 6     *if target is CaSR*

7  $c_1 = \frac{\min(\text{weight}_{p_2})_{p_2 \in \{1, \dots, n_2\}}}{2}$

8 else

9  $c_1 = \min(\text{weight}_{p_2})_{p_2 \in \{1, \dots, n_2\}}$

4  $\text{weight}_{p_3} = \frac{\text{score}_{p_3}^3}{\max_{l=1, \dots, n_3}(\text{score}_l^3)} c_1$

### **Weight of Type II positions**

7 for  $p_4 = 1: n_4$

8  $\text{weight}_{p_4} = \frac{\text{score}_{p_4}^4}{\max_{l=1, \dots, n_4}(\text{score}_l^4)} c_2$

528

### **529 Subfamily Specific Position Scores**

530 From the alignment we used to make subfamily specific profile HMMs, we randomly selected  
531 264 CaSR like sequences (same number of sequences as CaSRs) and took all CaSR (264  
532 proteins), GPRC6A (242 proteins) and TAS1Rs (TAS1R1 has 210, TAS1R2 has 173 and  
533 TAS1R3 has 273 proteins). We built an ML tree by using IQ-TREE multicore version 2.0.6[68]  
534 with automatic model selection[69] (-m MFP) and ultrafast bootstrap[70] (-bb 1000) parameters.  
535 For CaSR, GPRC6A, and TAS1Rs, we removed the positions from the multiple sequence  
536 alignment that correspond to a gap in the human receptor respectively. By using gap removed  
537 alignments and the ML tree, we did ancestral sequence reconstructions for each subfamily with  
538 IQ-TREE multicore version 2.0.6 with -m JTT+R10 model parameter[68]. We showed specific  
539 residues that have a SDP score higher than 5, on the structures. We used cyro-EM structure of  
540 CaSR (PDB:7DTV) and Swiss models[71] for GPRC6A and taste receptors since they do not  
541 have experimental structures. To visualize structures and residues we used UCSF Chimera  
542 tool[72].

543 We calculated SDP scores by a method extended from[27] by considering the phylogenetic  
544 trees and a phylogeny-based scoring approach, adjPHACT, based on the methodology of  
545 PHACT algorithm. The details of how we compute SDP score for any position k can be found in  
546 Algorithm 3. PHACT computes the tolerance for each amino acid for the query specie which is  
547 human by using a tree traversal approach. By checking the probability differences, PHACT  
548 detects the location of amino acid substitutions and compute weighted summation of positive  
549 probability differences based on the distance between the node of change and human. On the  
550 other hand, here we aim to determine the acceptability of each amino acid per subfamily. To

551 achieve this, we modify PHACT by starting the tree traversal from the root node and eliminating  
552 the node weighting approach. At the end, we have a probability distribution per position for each  
553 subfamily which is computed by considering the independent events. Again, we determine the  
554 representative amino acid for target subfamily by picking the most frequently observed amino  
555 acid and its adjPHACT score. For the remaining subfamilies, we keep the adjPHACT score of  
556 the representative amino acid of the target. Then, similar to [27] we check whether the same  
557 amino acid is conserved across all subfamilies. On the other hand, our approach differentiates  
558 from [27] in terms of considering multiple subfamilies and using adjPHACT scores which employ  
559 phylogenetic trees and ancestral reconstruction probabilities. In our approach, we compute the  
560 contribution of each subfamily to the SDP score by checking whether the representative amino  
561 acid of target has a high adjPHACT score in that subfamily (line 1). In the final SDP score for  
562 any position k is computed by considering the distance between target and other subfamilies  
563 (which is computed by considering the distance between root nodes), the conservation level of  
564 the target subfamily in terms of independent amino acid alterations and the individual score  
565 coming from each subfamily (line 3).

---

#### ALGORITHM 3: SDP SCORE FOR POSITION “K”

*Input: Amino acid with the highest adjPHACT score in the target group, aa; the adjPHACT score of aa for target,  $P_{aa}^T$ ; adjPHACT score of aa for other subfamilies  $i=1, \dots, n$ ,  $P_{aa}^i$ ; distance between target subfamily and subfamily i,  $d_i$ .*

1 *Compute score for each subfamily i,*

$$S_i = \exp(1) - \exp(P_{aa}^i).$$

2 *The overall weight,*

$$\omega = 1 - \max(P_{aa}^i).$$

3 *The SDP score for position k,*

$$SDP = P_{aa}^T + \omega \left( \sum_{i=1}^n \frac{1}{D_i} S_i \right)^{P_{aa}^T}$$

#### 566 Evolution of Class C GPCRs

567 We selected representative sequences from different taxonomic levels for each subfamily and  
568 264 CaSR-like sequences. We aligned them with MAFFT v7.221 einsi algorithm[63]. We built  
569 the ML tree by RAxML-NG-0.9.0 with the model JTT and transfer bootstrap expectation –bs-

570 metric fbp, the parameters[67]. We merged the ML trees of CaSR, GPRC6A and taste receptors  
571 by checking clades by using ETE toolkit [65].

## 572 **Machine Learning**

### 573 **Dataset and Feature Preparation**

574 To predict the consequence of a substitution in human CaSR, we used a gradient boosting-  
575 based machine learning algorithm, XGBoost[33]. We used XGBoost library for R[73] to train our  
576 model. We selected total of 337 loss and gain-of-function mutations from the literature[2] to train  
577 our model. Since we used conservation scores as features to train our model, we divided  
578 subfamily alignments and mutations randomly as 80% training and the remaining 20% test data  
579 before creating feature matrices to prevent information leakage. 25% of the training data was  
580 randomly picked as the validation data five times for cross validation. For each dataset split we  
581 used the sklearn train test split model with stratify option to keep loss-of-function to gain-of-  
582 function ratio almost the same in the datasets[74]. We calculated the conservation score of the  
583 reference amino acid and the substituted amino acid in human CaSR in each subfamily. The  
584 reference and the substituted amino acids were represented BLOSUM62 encoded matrices.  
585 Amino acid physico-chemical feature values Zimmerman polarity[75], average flexibility[76],  
586 Dayhoff[77], average buried area[78], Doolittle hydropathicity[79], atomic weight ratio[80],  
587 molecular weight, and bulkiness[75] from ProtScale database[81]; and domain information of  
588 the reference amino acid were used as other features. We normalized the physico-chemical  
589 feature values prior to model training. We repeated the whole random dataset splitting and  
590 feature preparation procedure 50 times to obtain more robust results.

### 591 **Model Selection and Parameter Tuning**

592 We picked the model parameters for each replication by applying a 5-fold cross-validation  
593 technique on the training set. We tuned the model parameters step-by-step using the same  
594 validation sets for each parameter to decrease the time complexity. We used the following order  
595 of model parameters, so that the parameter that has the highest impact on model outcome was  
596 tuned first: Eta and nrounds, gamma, maxdepth, subsample, colsample bytree, min child  
597 weight, lambda, alpha. We selected the maxdepth as 2, the minimum maxdepth value to  
598 prevent overfitting. We chose eta, gamma, colsample bytree, subsample, min child weight from  
599 the sets 0.00001,0.00002,..., 0.001,0,0.1,0.2,...,0.5, 0.5,0.55,...,1, 0.5,0.55,...,1, 1,2,...,6  
600 respectively. We selected regularization parameters lambda and alpha from the set 0, 1e-4, 1e-  
601 3, 1e-2, 1e-1, 1, 10, 100. We set nrounds parameter as 200.

602 **Performance Metrics**

603 We used the area under the receiver operating characteristic curve (AUROC) and the area  
604 under the precision-recall curve (AUPR) to evaluate the performance of our prediction model.  
605 AUROC and AUPR are performance measures that are widely used to evaluate the  
606 performance of binary classification problems. The higher the AUROC and AUPR, the better the  
607 model distinguishes classes. To understand how our model makes predictions, we used SHAP  
608 (SHapley Additive exPlanations) values. SHAP values provide an estimate of the contribution of  
609 each feature to the prediction made by the model[82]. We calculated SHAP values for our final  
610 model trained by all samples by using R shapviz package[83].

611 **Predictive Performance**

612 After we evaluated the performance of our machine learning algorithm over 50 replications, we  
613 used the whole dataset to train the model that we used to make predictions for every possible  
614 mutation in human CaSR. We selected model parameters by using 5-fold cross-validation  
615 technique on the whole dataset. To create a new test dataset, we took subfamily alignments of  
616 the species from the new Uniprot dataset that did not exist in the training data. We eliminated  
617 amino acids that are observed in the CaSR alignment as neutral. In each position we predicted  
618 the gain or loss-of -function class for any substitution. We did a literature search to find new  
619 clinical cases that cause either gain or loss of function mutations. We reported our predictions in  
620 the table.

621 **Acknowledgments**

622 This study was supported by EMBO Installation Grant no:4163 funded by TÜBİTAK (to OA).  
623 Ogun Adebali is supported by the BAGEP program of the Science Academy - Türkiye, and the  
624 TÜBA-GEBİP program of the Turkish Academy of Sciences.

625 **References**

- 626 1. Cook, A.E., et al., *Biased allosteric modulation at the CaS receptor engendered by*  
627 *structurally diverse calcimimetics*. British journal of pharmacology, 2015. **172**(1): p. 185-  
628 200.
- 629 2. Gorvin, C.M., *Molecular and clinical insights from studies of calcium-sensing receptor*  
630 *mutations*. J Mol Endocrinol, 2019. **63**(2): p. R1-R16.
- 631 3. Chen, X., et al., *Structural insights into the activation of human calcium-sensing receptor*.  
632 Elife, 2021. **10**.
- 633 4. Geng, Y., et al., *Structural mechanism of ligand activation in human calcium-sensing*  
634 *receptor*. Elife, 2016. **5**.

- 635 5. Ling, S., et al., *Structural mechanism of cooperative activation of the human calcium-*  
636 *sensing receptor by Ca(2+) ions and L-tryptophan*. *Cell Res*, 2021. **31**(4): p. 383-394.
- 637 6. Wootten, D., et al., *Mechanisms of signalling and biased agonism in G protein-coupled*  
638 *receptors*. *Nat Rev Mol Cell Biol*, 2018. **19**(10): p. 638-653.
- 639 7. Zhang, C., et al., *Structural basis for regulation of human calcium-sensing receptor by*  
640 *magnesium ions and an unexpected tryptophan derivative co-agonist*. *Sci Adv*, 2016.  
641 **2**(5): p. e1600241.
- 642 8. Gao, Y., et al., *Asymmetric activation of the calcium-sensing receptor homodimer*.  
643 *Nature*, 2021. **595**(7867): p. 455-459.
- 644 9. Park, J., et al., *Symmetric activation and modulation of the human calcium-sensing*  
645 *receptor*. *Proc Natl Acad Sci U S A*, 2021. **118**(51).
- 646 10. Wen, T., et al., *Structural basis for activation and allosteric modulation of full-length*  
647 *calcium-sensing receptor*. *Science Advances*, 2021. **7**(23): p. eabg1483.
- 648 11. Mun, H.-C., et al., *A double mutation in the extracellular Ca2+-sensing receptor's venus*  
649 *flytrap domain that selectively disables L-amino acid sensing*. *Journal of Biological*  
650 *Chemistry*, 2005. **280**(32): p. 29067-29072.
- 651 12. Zhang, C., et al., *Identification of an L-phenylalanine binding site enhancing the*  
652 *cooperative responses of the calcium-sensing receptor to calcium*. *Journal of Biological*  
653 *Chemistry*, 2014. **289**(8): p. 5296-5309.
- 654 13. Zhang, Z., et al., *Three adjacent serines in the extracellular domains of the CaR are*  
655 *required for L-amino acid-mediated potentiation of receptor function*. *Journal of*  
656 *Biological Chemistry*, 2002. **277**(37): p. 33727-33735.
- 657 14. Liu, H., et al., *Illuminating the allosteric modulation of the calcium-sensing receptor*.  
658 *Proceedings of the National Academy of Sciences*, 2020. **117**(35): p. 21711-21722.
- 659 15. Chagoyen, M., J.A. Garcia-Martin, and F. Pazos, *Practical analysis of specificity-*  
660 *determining residues in protein families*. *Brief Bioinform*, 2016. **17**(2): p. 255-61.
- 661 16. Studer, R.A., B.H. Dessailly, and C.A. Orengo, *Residue mutations and their impact on*  
662 *protein structure and function: detecting beneficial and pathogenic changes*. *Biochemical*  
663 *journal*, 2013. **449**(3): p. 581-594.
- 664 17. Kuru, N., et al., *PHACT: Phylogeny-Aware Computing of Tolerance for Missense*  
665 *Mutations*. *Mol Biol Evol*, 2022. **39**(6).
- 666 18. Pin, J.P., T. Galvez, and L. Prezeau, *Evolution, structure, and activation mechanism of*  
667 *family 3/C G-protein-coupled receptors*. *Pharmacol Ther*, 2003. **98**(3): p. 325-54.

- 668 19. Harpsoe, K., et al., *Structural insight to mutation effects uncover a common allosteric*  
669 *site in class C GPCRs*. Bioinformatics, 2017. **33**(8): p. 1116-1120.
- 670 20. Patil, I., *Visualizations with statistical details: The'ggstatsplot'approach*. Journal of Open  
671 Source Software, 2021. **6**(61): p. 3167.
- 672 21. Goes van Naters, W. and C. Mucignat-Caretta, *Frontiers in Neuroscience Drosophila*  
673 *Pheromones: From Reception to Perception*. Neurobiology of Chemical Communication.  
674 Boca Raton (FL): CRC Press/Taylor & Francis (c), 2014.
- 675 22. Brown, D., et al., *Subfamily hmms in functional genomics*. Pac Symp Biocomput, 2005:  
676 p. 322-33.
- 677 23. Srivastava, P.K., et al., *HMM-ModE--improved classification using profile hidden Markov*  
678 *models by optimising the discrimination threshold and modifying emission probabilities*  
679 *with negative training sequences*. BMC Bioinformatics, 2007. **8**: p. 104.
- 680 24. Roberts, M.S., et al., *Treatment of Autosomal Dominant Hypocalcemia Type 1 With the*  
681 *Calcilytic NPSP795 (SHP635)*. J Bone Miner Res, 2019. **34**(9): p. 1609-1618.
- 682 25. Pruitt, K.D., T. Tatusova, and D.R. Maglott, *NCBI reference sequences (RefSeq): a*  
683 *curated non-redundant sequence database of genomes, transcripts and proteins*.  
684 Nucleic Acids Res, 2007. **35**(Database issue): p. D61-5.
- 685 26. Gorvin, C.M., *Calcium-sensing receptor signaling—How human disease informs biology*.  
686 Current opinion in endocrine and metabolic research, 2021. **16**: p. 10-18.
- 687 27. Bradley, D. and P. Beltrao, *Evolution of protein kinase substrate recognition at the active*  
688 *site*. PLoS biology, 2019. **17**(6): p. e3000341.
- 689 28. Chun, L., W.H. Zhang, and J.F. Liu, *Structure and ligand recognition of class C GPCRs*.  
690 Acta Pharmacol Sin, 2012. **33**(3): p. 312-23.
- 691 29. Pi, M., S.K. Nishimoto, and L.D. Quarles, *GPRC6A: Jack of all metabolism (or master of*  
692 *none)*. Mol Metab, 2017. **6**(2): p. 185-193.
- 693 30. Nango, E., et al., *Taste substance binding elicits conformational change of taste receptor*  
694 *T1r heterodimer extracellular domains*. Sci Rep, 2016. **6**: p. 25745.
- 695 31. Kumari, R., C. Castillo, and A. Francesconi, *Agonist-dependent signaling by group I*  
696 *metabotropic glutamate receptors is regulated by association with lipid domains*. J Biol
- 697 Chem, 2013. **288**(44): p. 32004-19.
- 698 32. Nuemket, N., et al., *Structural basis for perception of diverse chemical substances by*  
699 *T1r taste receptors*. Nat Commun, 2017. **8**: p. 15530.

- 700 33. Chen, T. and C. Guestrin. *Xgboost: A scalable tree boosting system*. in *Proceedings of*  
701 *the 22nd acm sigkdd international conference on knowledge discovery and data mining*.  
702 2016.
- 703 34. Chou, K.J., et al., *A new missense mutation of calcium sensing receptor with isoleucine*  
704 *replaced by serine at codon 857 leading to type V Bartter syndrome*. *Exp Cell Res*,  
705 2022. **414**(1): p. 113080.
- 706 35. Moon, J.E., et al., *A cell function study on calcium regulation of a novel calcium-sensing*  
707 *receptor mutation (p.Tyr825Phe)*. *Ann Pediatr Endocrinol Metab*, 2021. **26**(1): p. 24-30.
- 708 36. Palmieri, S., et al., *Case Report: Unusual Presentations of Loss-of-Function Mutations of*  
709 *the Calcium-Sensing Receptor*. *Front Med (Lausanne)*, 2021. **8**: p. 809067.
- 710 37. Li, N., et al., *A novel homozygous mutation of the calcium-sensing receptor gene*  
711 *associated with apparent autosomal recessive inheritance of familial hypocalciuric*  
712 *hypercalcemia*. *Chin Med J (Engl)*, 2021. **134**(15): p. 1869-1871.
- 713 38. Hao, Y., et al., *Radiofrequency Ablation of Parathyroid Glands to Treat a Patient With*  
714 *Hypercalcemia Caused by a Novel Inactivating Mutation in CaSR*. *Front Endocrinol*  
715 *(Lausanne)*, 2021. **12**: p. 743517.
- 716 39. Tsuji, T., et al., *Autosomal Dominant Hypocalcemia With Atypical Urine Findings*  
717 *Accompanied by Novel CaSR Gene Mutation and VitD Deficiency*. *J Endocr Soc*, 2021.  
718 **5**(3): p. bva0190.
- 719 40. Dharmaraj, P., et al., *Neonatal Hypocalcemic Seizures in Offspring of a Mother With*  
720 *Familial Hypocalciuric Hypercalcemia Type 1 (FHH1)*. *J Clin Endocrinol Metab*, 2020.  
721 **105**(5).
- 722 41. Gomes, V., et al., *Autosomal dominant hypocalcaemia: identification of two novel*  
723 *variants of CASR gene*. *BMJ Case Rep*, 2020. **13**(6).
- 724 42. Magno, A.L., et al., *Functional Analysis of Calcium-Sensing Receptor Variants Identified*  
725 *in Families Provisionally Diagnosed with Familial Hypocalciuric Hypercalcemia*. *Calcif*  
726 *Tissue Int*, 2020. **107**(3): p. 230-239.
- 727 43. Majumdar, S.K., et al., *A Novel Variant in the Calcium-Sensing Receptor Associated with*  
728 *Familial Hypocalciuric Hypercalcemia and Low-to-Normal PTH*. *Case Rep Endocrinol*,  
729 2020. **2020**: p. 8752610.
- 730 44. Zajickova, K., et al., *Familial hypocalciuric hypercalcemia in an index male: grey zones*  
731 *of the differential diagnosis from primary hyperparathyroidism in a 13-year clinical follow*  
732 *up*. *Physiol Res*, 2020. **69**(Suppl 2): p. S321-S328.

- 733 45. Sagi, S.V., et al., *A novel CASR variant in a family with familial hypocalciuric*  
734 *hypercalcaemia and primary hyperparathyroidism*. Endocrinol Diabetes Metab Case  
735 Rep, 2020. **2020**.
- 736 46. Dong, Q., et al., *[Clinical and genetic analysis of a child with neonatal severe*  
737 *parathyroidism]*. Zhonghua Yi Xue Yi Chuan Xue Za Zhi, 2020. **37**(11): p. 1247-1249.
- 738 47. Hawkes, C.P., D.I. Shulman, and M.A. Levine, *Recombinant human parathyroid*  
739 *hormone (1-84) is effective in CASR-associated hypoparathyroidism*. Eur J Endocrinol,  
740 2020. **183**(6): p. K13-K21.
- 741 48. Wejaphikul, K., et al., *Subtotal parathyroidectomy successfully controls calcium levels of*  
742 *patients with neonatal severe hyperparathyroidism carrying a novel CASR mutation*.  
743 Hormone Research in Paediatrics, 2023: p. 1-7.
- 744 49. Courtney, A., et al., *Familial hypocalciuric hypercalcaemia type 1 caused by a novel*  
745 *heterozygous missense variant in the CaSR gene, p (His41Arg): two case reports*. BMC  
746 Endocrine Disorders, 2022. **22**(1): p. 324.
- 747 50. Bletsis, P., et al., *A Novel missense CASR gene sequence variation resulting in familial*  
748 *hypocalciuric hypercalcemia*. AACE Clinical Case Reports, 2022. **8**(5): p. 194-198.
- 749 51. Wu, Y., et al., *Autosomal dominant hypocalcemia with a novel CASR mutation: a case*  
750 *study and literature review*. Journal of International Medical Research, 2022. **50**(7): p.  
751 03000605221110489.
- 752 52. Coughlan, A., F. Khan, and M. Brassill, *A Novel Genetic Variant Resulting in Familial*  
753 *Hypocalciuric Hypercalcaemia*. Irish Medical Journal, 2022. **115**(2): p. 545-545.
- 754 53. Mullin, B.H., et al., *Functional assessment of calcium-sensing receptor variants confirms*  
755 *familial hypocalciuric hypercalcemia*. Journal of the Endocrine Society, 2022. **6**(5): p.  
756 bvac025.
- 757 54. Jones, E.M., et al., *Structural and functional characterization of G protein-coupled*  
758 *receptors with deep mutational scanning*. Elife, 2020. **9**: p. e54895.
- 759 55. Alirezaie, N., et al., *ClinPred: prediction tool to identify disease-relevant nonsynonymous*  
760 *single-nucleotide variants*. The American Journal of Human Genetics, 2018. **103**(4): p.  
761 474-483.
- 762 56. Ioannidis, N.M., et al., *REVEL: an ensemble method for predicting the pathogenicity of*  
763 *rare missense variants*. The American Journal of Human Genetics, 2016. **99**(4): p. 877-  
764 885.
- 765 57. Rentzsch, P., et al., *CADD: predicting the deleteriousness of variants throughout the*  
766 *human genome*. Nucleic acids research, 2019. **47**(D1): p. D886-D894.

- 767 58. Rogers, M.F., et al., *FATHMM-XF: accurate prediction of pathogenic point mutations via*  
768 *extended features*. *Bioinformatics*, 2018. **34**(3): p. 511-513.
- 769 59. Eddy, S.R., *Accelerated profile HMM searches*. *PLoS computational biology*, 2011.  
770 **7**(10): p. e1002195.
- 771 60. Finn, R.D., et al., *The Pfam protein families database: towards a more sustainable*  
772 *future*. *Nucleic acids research*, 2016. **44**(D1): p. D279-D285.
- 773 61. *UniProt: the universal protein knowledgebase*. *Nucleic acids research*, 2017. **45**(D1): p.  
774 D158-D169.
- 775 62. Altschul, S.F., et al., *Basic local alignment search tool*. *Journal of molecular biology*,  
776 1990. **215**(3): p. 403-410.
- 777 63. Yamada, K.D., K. Tomii, and K. Katoh, *Application of the MAFFT sequence alignment*  
778 *program to large data—reexamination of the usefulness of chained guide trees*.  
779 *Bioinformatics*, 2016. **32**(21): p. 3246-3251.
- 780 64. Stamatakis, A., *RAxML version 8: a tool for phylogenetic analysis and post-analysis of*  
781 *large phylogenies*. *Bioinformatics*, 2014. **30**(9): p. 1312-1313.
- 782 65. Huerta-Cepas, J., F. Serra, and P. Bork, *ETE 3: reconstruction, analysis, and*  
783 *visualization of phylogenomic data*. *Molecular biology and evolution*, 2016. **33**(6): p.  
784 1635-1638.
- 785 66. Capella-Gutierrez, S., J.M. Silla-Martinez, and T. Gabaldon, *trimAl: a tool for automated*  
786 *alignment trimming in large-scale phylogenetic analyses*. *Bioinformatics*, 2009. **25**(15): p.  
787 1972-3.
- 788 67. Kozlov, A.M., et al., *RAxML-NG: a fast, scalable and user-friendly tool for maximum*  
789 *likelihood phylogenetic inference*. *Bioinformatics*, 2019. **35**(21): p. 4453-4455.
- 790 68. Nguyen, L.-T., et al., *IQ-TREE: a fast and effective stochastic algorithm for estimating*  
791 *maximum-likelihood phylogenies*. *Molecular biology and evolution*, 2015. **32**(1): p. 268-  
792 274.
- 793 69. Kalyaanamoorthy, S., et al., *ModelFinder: fast model selection for accurate phylogenetic*  
794 *estimates*. *Nature methods*, 2017. **14**(6): p. 587-589.
- 795 70. Hoang, D.T., et al., *UFBoot2: improving the ultrafast bootstrap approximation*. *Molecular*  
796 *biology and evolution*, 2018. **35**(2): p. 518-522.
- 797 71. Waterhouse, A., et al., *SWISS-MODEL: homology modelling of protein structures and*  
798 *complexes*. *Nucleic acids research*, 2018. **46**(W1): p. W296-W303.
- 799 72. Pettersen, E.F., et al., *UCSF Chimera—a visualization system for exploratory research*  
800 *and analysis*. *J Comput Chem*, 2004. **25**(13): p. 1605-12.

- 801 73. Chen, T., et al., *Xgboost: extreme gradient boosting. R package version 04-2*. OS  
802 Independent, 2015.
- 803 74. Pedregosa, F., et al., *Scikit-learn: Machine learning in Python*. the Journal of machine  
804 Learning research, 2011. **12**: p. 2825-2830.
- 805 75. Zimmerman, J., N. Eliezer, and R. Simha, *The characterization of amino acid sequences*  
806 *in proteins by statistical methods*. Journal of theoretical biology, 1968. **21**(2): p. 170-201.
- 807 76. Bhaskaran, R. and P. Ponnuswamy, *Positional flexibilities of amino acid residues in*  
808 *globular proteins*. International Journal of Peptide and Protein Research, 1988. **32**(4): p.  
809 241-255.
- 810 77. Barker, W.C., L.K. Ketcham, and M.O. Dayhoff, *A comprehensive examination of protein*  
811 *sequences for evidence of internal gene duplication*. Journal of Molecular Evolution,  
812 1978. **10**: p. 265-281.
- 813 78. Rose, G.D., et al., *Hydrophobicity of amino acid residues in globular proteins*. Science,  
814 1985. **229**(4716): p. 834-838.
- 815 79. Kyte, J. and R.F. Doolittle, *A simple method for displaying the hydropathic character of a*  
816 *protein*. Journal of molecular biology, 1982. **157**(1): p. 105-132.
- 817 80. Grantham, R., *Amino acid difference formula to help explain protein evolution*. science,  
818 1974. **185**(4154): p. 862-864.
- 819 81. Walker, J.M., *The proteomics protocols handbook*. 2005: Springer.
- 820 82. Lundberg, S.M. and S.-I. Lee, *A unified approach to interpreting model predictions*.  
821 Advances in neural information processing systems, 2017. **30**.
- 822 83. Mayer, M. *shapviz: SHAP Visualizations. R package version 0.9.0*. 2023; Available from:  
823 <https://github.com/ModelOriented/shapviz>.

824

825

826

827

828

829

830

831

832

833

834

835